Book Value per Share: Alector Inc. (ALEC)

Alector (ALEC) - corporate logo

The primary risk for Alector, Inc. (ALEC) remains the potential failure of Alzheimer's drug trials and a heavy reliance on external capital. The business relies on an optimized biomaterial delivery system, which reduces costs in developing treatments for nerve cell degeneration. This price chart shows Alector, Inc. (ALEC) shares trading without internal profit sources, as the indicator stands at -0.09, with development funded by partner grants.

Alector Therapeutics (ALEC) Equity per Share: for the period 07/04/2022 - 10/27/2026

Alector Inc. - analytical breakdowns and key metrics (ALEC)

- price and consensus price forecast:
Stock Price Alector Therapeutics|ALEC - Average Forecast Price
- market capitalization data:
Market Capitalization Alector, Inc.|ALEC - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Alector|ALEC - Accounting Capitalization|Market Capitalization to Book Value Ratio alector.com|ALEC - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Alector, Inc.|ALEC - Long-Term Debt to Capital|Short-Term Debt to Equity Alector Therapeutics|ALEC - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Alector, Inc.
Fundamental company valuation:alector.com, ALEC
Manufactured products of Alector Therapeutics

The development of immunological therapies for neurodegenerative diseases allows Alector, Inc. (ALEC) to strengthen its position within the high-tech neurobiotech sector. By analyzing the trend in book value per share, an investor assesses the company's net assets minus all liabilities, which determines the real value of the equity stake and confirms the business's financial stability between quarterly reports.

Competitors of Alector, Inc. (ALEC)

BIIB (Biogen Corp) - Book Value per Share|NBIX - Net Asset Value per Share|RGC (Regencell Bioscience) - Book Value per Share|AXSM (axsome.com) - Accounting Value per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|Trevi Corp (TRVI) - Net Asset Value per Share|PRAX (Praxis Precision Medicines) - Book Value per Share|Book Value per Share AVXL|Net Assets per Single Share CeriBell (CBLL)|Net Assets per Single Share Prothena Corporation (PRTA)|ANNX: Book Value per Share|Net Asset Value per Share Omeros Corp OMER|NGNE: Book Value per Share|acimmune.com (ACIU) - Accounting Value per Share|VYGR - Accounting Value per Share|NMRA (Neumora) - Book Price of a Share|Net Assets per Single Share SCLX (Scilex Holding Co.)|Net Asset Value per Share TVGN|Alpha Cognition (ACOG) - Net Assets per Single Share|Accounting Value of a Share Cognition Therapeutics Inc. CGTX|Accounting Value per Share Inhibikase Therapeutics, Inc.|Accounting Value of a Share Cassava Sciences Inc SAVA|Book Value per Share ASRT (Assertio Therapeutics)|COYA: Net Assets per Share|Net Assets per Single Share vistagen.com|Ovid Therapeutics (OVID) - Equity per Share|Book Value per Share ABOS|Accounting Value per Share CervoMed, Inc. (CRVO)|ATHE (Alterity Therapeutics) - Accounting Value per Share|Net Assets per Share clene.com (CLNN)|Book Value per Share PEPG (PepGen)|Jupiter Neurosciences, Inc. - Book Value per Share|RLMD - Net Assets per Single Share|ANVS - Net Assets per Single Share|Book Value per Share GRCE|Firefly Neuro (AIFF) - Net Asset Value per Share|Book Value per Share KLTO|Accounting Value per Share NRSN|Net Assets per Single Share Reviva Pharmaceuticals Holdings, Inc. RVPH|Equity per Share metaviatx.com (MTVA)|NRXS: Book Value per Share|HSDT - Net Asset Value per Share|Passage Bio Corp - Accounting Value per Share|NEUP: Book Value per Share|Net Assets per Single Share Minerva Neurosciences, Inc. NERV|ATHA (Athira Pharma Inc) - Accounting Value of a Share|Net Assets per Single Share ADXN (Addex Therapeutics, Ltd.)|Net Asset Value per Share Alzamend|Book Value per Share CYCN|Book Value per Share PTIX (protagenic.com)|Net Assets per Single Share Pasithea Therapeutics Corp. KTTA|Net Assets per Single Share Cortigent Inc CRGT|ATXI (Avenue Therapeutics, Inc) - Book Value per Share|BCLI - Net Asset Value per Share|CARA (Cara Therapeutics, Inc.) - Book Value per Share|Accounting Value per Share chromocell.com|Eliem Therapeutics, Inc. (ELYM) - Accounting Value per Share|Book Price of a Share ITCI|Longboard Pharma - Net Assets per Single Share|Net Asset Value per Share MRNS (Marinus Pharma)|Net Assets per Single Share NKGen Biotech, Inc.|NRBO - Accounting Value of a Share|Accounting Value per Share Sage Therapeutics (SAGE)|SNPX - Accounting Value of a Share|Trevena, Inc - Book Value per Share|VIGL (Vigil Neuroscience, Inc.) - Net Assets per Share|Net Assets per Single Share Anew Medical (WENA)|Equity per Share cerevel.com